Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2019 (Specifically November 11, 2019)
Context: The filing serves to incorporate a press release by reference regarding a significant intellectual property milestone for the Company's drug candidate, Piclidenoson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on a corporate event rather than a financial statement.
Material Changes
Intellectual Property Milestone: On November 11, 2019, the U.S. Patent and Trademark Office issued Patent #10,265,337 to the Company.
Patent Title: "Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment."
Application: The patent covers the Company's drug candidate, Piclidenoson, for the treatment of osteoarthritis in mammals.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates the "Forward Looking Statements" from the attached press release (Exhibit 99.1) into the Company's Registration Statements on Form S-8 and Form F-3.
Risks and Contingencies: No specific risks or contingencies are detailed within the body of this filing text, other than the standard incorporation of forward-looking statements which typically contain risk factors.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed forward-looking statements and risk factors.
- Confirm the scope and jurisdiction of Patent #10,265,337 regarding the treatment of osteoarthritis.
- Review the Company's latest Form 20-F or 10-Q for current financial status, as this filing contains no financial data.
- Monitor the development timeline for Piclidenoson following this patent issuance.